What IBD Physicians Can Learn from Major League Baseball Managers
DOI:
https://doi.org/10.17140/GOJ-4-130Abstract
Yogi Berra philosophized, “You can observe a lot by just watching.” Physicians managing inflammatory bowel disease (IBD) patients are constantly exposed to the recent literature, the visiting pharmaceutical representatives, and to the valuable presentations by the academic experts at the annual meetings. In my opinion, these presentations too often are advanced in a vacuum of unconvincing compartmentalization rather than as a well-choreographed management strategy that considers both the impact of any IBD drug and the nearly certain likelihood of a patient’s failed response or eventual relapse.
References
Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): A multcentre, randomized, controlled phase 3 trial. Lancet. 2018; 390: 2779-2789. doi: 10.1016/S0140-6736(17)32641-7
Ungaro R, Colombel JF, Lissoos T, et al. A treat-to-target update in ulcerative colitis: A systematic review. Amer J Gastro. 2019; 114: 874-883. doi: 10.14309/ajg.0000000000000183
Baseball-Reference. MLB stats, scores, history, and records, 2019. Web site. Baseball-Reference.com. Accessed October 31, 2019.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013; 369: 711-721. doi: 10.1056/NEJMoa1215739
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomized trial. Lancet. 2002; 359: 1541-1549. doi: 10.1016/S0140-6736(02)08512-
Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease. Gastroenterology. 2007; 132(1): 52-65. doi: 10.1053/j. gastro.2006.11.041
Vasudevan A, Gibson PR, vanLangenberg DR. Time to clini-cal response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told. World J Gastroenterol. 2017: 23(35): 6385-6402. doi: 10.3748/ wjg.v23.i35.6385
Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the sec-ond year of therapy. Aliment Pharmacol Ther. 2018: 48(1): 65-77. doi: 10.1111/apt.14794
Murthy SK, Begum J, Benchimol EL, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitaliza-tion and intestinal resection rates in inflammatory bowel diseases: A population-based interrupted time series study. Gut. 2019; pii: gutjnl-2019-318440. doi: 10.1136/gutjnl-2019-318440 Opinion | Volume 4 | Number 1|
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gastro (GOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.